Why Cencora (COR) is a Top Value Stock for the Long-Term

Zacks identifies Cencora (COR), a pharmaceutical services company, as a compelling long-term value stock, aligning with its proprietary investment methodology. Despite a #3 (Hold) Zacks Rank, COR exhibits strong fundamentals with an 'A' VGM and Value Style Score, driven by an attractive 18.57 forward P/E and recent upward revisions to its fiscal 2025 earnings estimates, which increased the consensus to $15.88 per share.

Analysis

Cencora (COR) presents a compelling profile as a long-term value holding, according to a Zacks analysis. Despite a neutral Zacks Rank of #3 (Hold), the company scores an 'A' for both its Value and its composite VGM Style Score, signaling underlying strength. The positive value assessment is supported by an attractive forward P/E ratio of 18.57. Furthermore, forward-looking sentiment appears positive, with five analysts having revised fiscal 2025 earnings estimates upward over the last 60 days, lifting the consensus estimate by $0.13 to $15.88 per share. This is complemented by a historical track record of positive performance, evidenced by an average earnings surprise of +6.2%. The analysis suggests that for stocks with a 'Hold' rating, strong style scores like COR's can indicate potential upside, making it a noteworthy candidate for value-focused portfolios.

Key Decisions for Investors

• Value-oriented investors should consider Cencora for their watchlist, given its 'A' grade for value, a forward P/E of 18.57, and positive consensus earnings revisions.
• Given the neutral #3 (Hold) Zacks Rank, investors may want to monitor for a potential upgrade to a #1 (Strong Buy) or #2 (Buy) rank as a stronger confirmation signal before initiating or adding to a position.
• Investors should scrutinize upcoming earnings reports to confirm if the company can continue its trend of positive surprises, which currently averages +6.2%, as this performance is critical to validating the upward revisions in fiscal 2025 estimates.